<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Aging Clin Exp Res</journal-id><journal-id journal-id-type="iso-abbrev">Aging Clin Exp Res</journal-id><journal-title-group><journal-title>Aging Clinical and Experimental Research</journal-title></journal-title-group><issn pub-type="ppub">1594-0667</issn><issn pub-type="epub">1720-8319</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39373829</article-id><article-id pub-id-type="pmc">PMC11458640</article-id>
<article-id pub-id-type="publisher-id">2851</article-id><article-id pub-id-type="doi">10.1007/s40520-024-02851-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Association between statin usage and mortality outcomes in aging U.S. cancer survivors: a nationwide cohort study</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ding</surname><given-names>Shan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Yang</surname><given-names>Fengling</given-names></name><address><email>yangfengling0634@163.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lai</surname><given-names>Pan</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Weiwen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Minze</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ge</surname><given-names>Yijun</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Liting</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Shaozhuang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Jiaqi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ye</surname><given-names>Yanrong</given-names></name><address><email>ye.yanrong@zs-hospital.sh.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013q1eq08</institution-id><institution-id institution-id-type="GRID">grid.8547.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0125 2443</institution-id><institution>Zhongshan Hospital (Xiamen), </institution><institution>Fudan University, </institution></institution-wrap>Xiamen, 361015 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/030e09f60</institution-id><institution-id institution-id-type="GRID">grid.412683.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1758 0400</institution-id><institution>Longyan First Affiliated Hospital of Fujian Medical University, </institution></institution-wrap>Longyan, 364000 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02z1vqm45</institution-id><institution-id institution-id-type="GRID">grid.411472.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1764 1621</institution-id><institution>Peking University First Hospital, </institution></institution-wrap>Beijing, 100034 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013q1eq08</institution-id><institution-id institution-id-type="GRID">grid.8547.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0125 2443</institution-id><institution>Zhongshan Hospital, </institution><institution>Fudan University, </institution></institution-wrap>Shanghai, 200032 China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01zvqw119</institution-id><institution-id institution-id-type="GRID">grid.252547.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0705 7067</institution-id><institution>Faculty of Health and Environmental Sciences, </institution><institution>Auckland University of Technology, </institution></institution-wrap>Auckland, 0627 New Zealand </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0064kty71</institution-id><institution-id institution-id-type="GRID">grid.12981.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2360 039X</institution-id><institution>Shenzhen Campus of Sun Yat-Sen University, </institution></institution-wrap>Shenzhen, 518107 China </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2024</year></pub-date><volume>36</volume><issue>1</issue><elocation-id>200</elocation-id><history><date date-type="received"><day>3</day><month>4</month><year>2024</year></date><date date-type="accepted"><day>13</day><month>9</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024, corrected publication 2025</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">The population of Aging cancer survivors in the United States has surged to over 16.9&#x000a0;million. Research on the relationship between statin usage and post-cancer survival rates remains limited.</p></sec><sec><title>Aims</title><p id="Par2">This study aims to investigate the association between statin use and various causes of mortality among aging cancer survivors.</p></sec><sec><title>Methods</title><p id="Par3">We analyzed NHANES data from 1999 to 2018, Statin usage, both hydrophilic and lipophilic, was derived from NHANES prescription records. We utilized Cox proportional hazards models to associate statin utilization with mortality, differentiating causes of death according to statin type and patterns of use.</p></sec><sec><title>Results</title><p id="Par4">Within a cohort of 2,968 participants, statin usage was categorized into non-users (1,738), hydrophilic statin users (216), and lipophilic statin users (982). Compared to those who did not use statins, individuals prescribed hydrophilic statins did not show a reduced risk of all-cause mortality (adjusted hazard ratio [HR] 1.01; 95% confidence interval [CI] 0.72&#x02013;1.41; <italic>P</italic>&#x02009;=&#x02009;0.960), as outlined in Model 3. In contrast, the group receiving lipophilic statins exhibited a notable decrease in all-cause mortality risk (adjusted HR, 0.77; <italic>P</italic>&#x02009;=&#x02009;0.003). Nonetheless, both hydrophilic and lipophilic statins were effective in diminishing the risk associated with cancer from its onset until death, with hydrophilic statins showing a greater level of efficacy.</p></sec><sec><title>Discussion</title><p id="Par5">The potential of statins to reduce cancer-related mortality may provide avenues for targeted clinical interventions and management strategies.</p></sec><sec><title>Conclusions</title><p id="Par6">Our study reveals that the use of lipophilic statins is significantly associated with lower all-cause and cancer-cause mortality risks among aging cancer survivors.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s40520-024-02851-2.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cancer survivors</kwd><kwd>Mortality</kwd><kwd>Statins</kwd><kwd>NHANES</kwd><kwd>Aging</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Switzerland AG 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par7">As advancements in cancer therapies continue to flourish, the population of cancer survivors is expanding at a remarkable rate, with over 16.9&#x000a0;million individuals in the United States who have conquered the disease [<xref ref-type="bibr" rid="CR1">1</xref>]. Within this extensive community, as we embrace the era of aging, cancer survivors are progressively transitioning into their elderly phase. However, this group faces the ongoing and delayed effects of various cancers and their treatments, which regrettably might reduce life expectancy [<xref ref-type="bibr" rid="CR2">2</xref>]. Consequently, it is imperative to accelerate the development of viable strategies that these elder survivors can adopt to enhance their long-term health outcomes.</p><p id="Par8">Statins, are renowned for their ability to lower blood cholesterol levels and serve as preventative and therapeutic agents in the realm of cardiovascular disease with pronounced efficacy and minimal side effects [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Increased evidence suggests that the benefits of statins extend beyond their cardiovascular applications. They are associated with a diminished occurrence of neurological disorders [<xref ref-type="bibr" rid="CR5">5</xref>], as well as a decreased mortality risk in the context of breast [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>], prostate [<xref ref-type="bibr" rid="CR8">8</xref>], colorectal [<xref ref-type="bibr" rid="CR9">9</xref>], and renal cell carcinomas [<xref ref-type="bibr" rid="CR10">10</xref>]. Moreover, these compounds exhibit pleiotropic properties that span anti-inflammatory and anti-tumoral cell proliferation activities [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>], potentially harbouring stand-alone anti-cancer effects [<xref ref-type="bibr" rid="CR14">14</xref>]. Statins are classified into hydrophilic and lipophilic statins, which have different intracellular effects depending on their chemical structure. Lipophilic statins show a greater ability to penetrate the cell membrane and also have higher pro-apoptotic activity than hydrophilic statins [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Due to this higher cytotoxic potential, lipophilic statins may be beneficial in cancer treatment [<xref ref-type="bibr" rid="CR17">17</xref>]. There is a noticeable lack of research on the relationship between statin use and post-cancer survival rates, especially among older cancer survivors. Moreover, additional epidemiological studies are necessary to shed light on the synergistic effects and potential advantages of using different types of statins(hydrophilic and lipophilic) to improve survival following a cancer diagnosis.</p><p id="Par9">In the present study, we used the 1999&#x02013;2018 National Health and Nutrition Examination Survey (NHANES) data, to detect the relationships of statins use with the mortality of aging cancer survivors to investigate whether statin use may improve long-term health outcomes of aging cancer survivors.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study population</title><p id="Par10">The National Health and Nutrition Examination Survey (NHANES) is a series of independent, nationally representative cross-sectional surveys conducted by the National Center for Health Statistics. Detailed information on recruitment, procedures, population characteristics, and study design is available through the Centers for Disease Control and Prevention (<ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/nchs/nhanes/index.htm">https://www.cdc.gov/nchs/nhanes/index.htm</ext-link>). NHANES was approved by the National Center for Health Statistics Research Ethics Review Board, and all participants provided written informed consent.</p><p id="Par11">For our study, we utilized NHANES 1999&#x02013;2018 data from cancer survivors aged 65 years or older. We excluded missing medication data population (<italic>n</italic>&#x02009;=&#x02009;31), and missing follow-up information population (<italic>n</italic>&#x02009;=&#x02009;1). Resulting in 2,936 adult subjects were included in the final analysis (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>)</p><p id="Par12">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Flowchart</p></caption><graphic xlink:href="40520_2024_2851_Fig1_HTML" id="d33e384"/></fig>
</p></sec><sec id="Sec4"><title>Exposure and study variables</title><p id="Par13">In the NHANES database, participants reported drug use in the prescription drug section of the sample person questionnaire interview, providing categories of therapeutic drugs associated with each drug and ingredient. Additionally, the use of statins occurs after the diagnosis of cancer. Statin users were defined by identifying unique generic codes from the Multum Lexicon drug database [<xref ref-type="bibr" rid="CR18">18</xref>]. We used the following prescription drugs as statins for this analysis/The prescription drugs considered as statins for this analysis were: lipophilic statins (simvastatin, fluvastatin, pitavastatin, lovastatin and atorvastatin) and hydrophilic statins (rosuvastatin and pravastatin). In our cohort, participants were categorized based on statin use and the use of different types of statins: (1) No statin group; (2) Statin group: (a) Hydrophilic statins; (b) Lipophilic statins (The rest).</p></sec><sec id="Sec5"><title>Diagnosis of cancer</title><p id="Par14">Information regarding cancer diagnoses was gathered through face-to-face interviews.</p><p id="Par15">These interviews included details on up to three types of cancer diagnoses and the respective ages at which each diagnosis occurred. Participants were asked, &#x0201c;Has a doctor or another health professional ever informed you of having cancer or any form of malignancy?&#x0201d; Those affirming this question were identified as cancer survivors and further queried about the specific type of cancer and their age at the time of initial diagnosis. The time elapsed since the first cancer diagnosis was determined by subtracting the age at the first diagnosis from the current age of the participant. eTable 1 provides a detailed breakdown of cancer survivors by type and sex, based on data from the NHANES 2007&#x02013;2018.</p></sec><sec id="Sec6"><title>Defining variables of interest</title><p id="Par16">Participants self-reported age, gender, race, and education. CVD was defined for self-reported coronary heart disease or congestive heart failure or angina or heart attack or stroke [<xref ref-type="bibr" rid="CR19">19</xref>]. Dyslipidemia was defined for LDL&#x02009;&#x0003e;&#x02009;130&#x000a0;mg/dL or HDL&#x02009;&#x0003c;&#x02009;40&#x000a0;mg/dL, and was independent of the use of statins. Diabetes was defined by treatment of diabetes, self-reported history of diabetes, or glycosylated hemoglobin (HbA1c)&#x02009;&#x02265;&#x02009;6.5% [<xref ref-type="bibr" rid="CR20">20</xref>]. Hypertension was defined by using the 2017 ACC/AHA/ MS guidelines [<xref ref-type="bibr" rid="CR21">21</xref>]. Participants were classified as smokers if they smoked&#x02009;&#x02265;&#x02009;100 cigarettes during their lifetime [<xref ref-type="bibr" rid="CR22">22</xref>].</p></sec><sec id="Sec7"><title>Determination of mortality outcomes</title><p id="Par17">NHANES is associated with death certificate records in the National Death Index (NDI), which determines the outcome of a death by linkage to National Death Index (NDI) records [<xref ref-type="bibr" rid="CR23">23</xref>]. Cause-specific deaths are determined according to the International Classification of Diseases, Tenth Revision (ICD-10) identified and National Center for Health Statistics (NCHS) classified cardiac diseases (054&#x02013;064), malignant neoplasms (019&#x02013;043), and all other causes (010) [<xref ref-type="bibr" rid="CR24">24</xref>]. Mortality follow-up data as of December 31, 2019 for 1999&#x02013;2018 NHANES participants.</p></sec><sec id="Sec8"><title>Statistical analysis</title><p id="Par18">In accordance with the instructions for using NHANES data, we considered complex survey design factors. Their recommended weights were used for analysis, and continuous variables were expressed as mean&#x02009;&#x000b1;&#x02009;standard deviation and statistically analyzed using one-way ANOVA, while for categorical variables counts and proportions (after weighting) were given, using card method tests [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par19">To assess the incidence rate of all-cause mortality events across groups defined by varying levels of statin usage, we employed Kaplan-Meier survival analysis, with differences among the groups being assessed using log-rank tests. In our study, stratified Cox proportional hazard modeling was utilized to explore the relationship between endpoints and statin use. We classified causes of death into four categories: all-cause mortality, cardiovascular mortality, cancer-related mortality, and mortality from other causes. The data were categorized according to the use of statins and the use of different types of statins as follows: (1) No statin group; (2) Statin group: (a) Hydrophilic statins; (b) Lipophilic statins (The rest). Three Cox regression models were developed to examine the association between statin use and mortality in the cancer population: Model 1 (unadjusted); Model 2 adjusted for gender, age, and race/ethnicity; and Model 3 adjusted for gender, age, race/ethnicity, education level, BMI, smoking status, alcohol use, dyslipidemia, hypertension, diabetes, and CVD. To ascertain the reliability of the association between statin use and cancer survivors, we analyzed the risk of cancer diagnosis to death in relation to statin usage. Additionally, we conducted sensitivity analyses by excluding deaths within the first two years of observation, followed by a re-evaluation of the primary outcomes.</p><p id="Par20">All analyses were performed using R 4.3.1 as well as a two-sided <italic>P</italic>-value&#x02009;&#x0003c;&#x02009;0.05 indicating that all analyses were significant.</p></sec></sec><sec id="Sec9" sec-type="results"><title>Result</title><p id="Par21">Among the cohort of 2,968 aging evaluated, 1,738 did not (utilize/use) statins, 216 were prescribed hydrophilic statins, and 982 were administered lipophilic statins, accounting for the remainder. The baseline characteristics of the participants, categorized by the extent and type of statin usage, are depicted in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. When juxtaposed with the non-statin group, individuals in the statin group were exhibited a decreased proportion of male constituents (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). Moreover, a higher prevalence of CVD, hypertension, and diabetes mellitus were observed in no statin group, yet a diminished frequency of dyslipidemia were noted. However, the LDL-C, HDL-C, and TC were markedly decreased in the statin group in contrast to their counterparts in the no statin group, with all noted differences reaching statistical significance (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001).</p><p id="Par22">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics of statin users and nonusers among aing cancer survivors&#x02014;NHAMES 1999&#x02013;2018</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Variable</th><th align="left" rowspan="2">Total</th><th align="left" rowspan="2">No statin</th><th align="left" colspan="2">Statin</th><th align="left" rowspan="2"><italic>P</italic>-value</th></tr><tr><th align="left">Hydrophilic statins</th><th align="left">Lipophilic statins (The rest)</th></tr></thead><tbody><tr><td align="left"><bold>Age (year)</bold>, <bold>SD</bold></td><td align="left">74.5&#x02009;&#x000b1;&#x02009;0.2</td><td align="left">74.5&#x02009;&#x000b1;&#x02009;0.2</td><td align="left">75.2&#x02009;&#x000b1;&#x02009;0.4</td><td align="left">74.2&#x02009;&#x000b1;&#x02009;0.2</td><td align="left">0.079</td></tr><tr><td align="left"><bold>Female</bold>, <bold>n (%)</bold></td><td align="left">28.3(0.1)</td><td align="left">27.7(0.2)</td><td align="left">28.8(0.5)</td><td align="left">29.1(0.2)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left"><bold>Race</bold>, <bold>n (%)</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">0.629</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Mexican American</td><td align="left">149(1.4)</td><td align="left">95(1.4)</td><td align="left">10(1.1)</td><td align="left">44(1.5)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Non-Hispanic Black</td><td align="left">360(4.7)</td><td align="left">210(4.7)</td><td align="left">22(3.6)</td><td align="left" colspan="2">128(4.8)</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Non-Hispanic White</td><td align="left">2209(89.3)</td><td align="left">1302(89.1)</td><td align="left">168(91.6)</td><td align="left" colspan="2">739(89.1)</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Other Hispanic</td><td align="left">111(1.8)</td><td align="left">72(2.1)</td><td align="left">6(1.1)</td><td align="left">33(1.4)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Other Race</td><td align="left">107(2.9)</td><td align="left">59(2.7)</td><td align="left">10(2.6)</td><td align="left">38(3.3)</td><td align="left"/></tr><tr><td align="left"><bold>Education level</bold>, <bold>n (%)</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">0.162</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x0003c;&#x02009;12</td><td align="left">756(18.2)</td><td align="left">461(19.4)</td><td align="left">52(16.4)</td><td align="left" colspan="2">243(16.6)</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;12</td><td align="left">1065(35.7)</td><td align="left">644(35.8)</td><td align="left">66(30.4)</td><td align="left" colspan="2">355(36.7)</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x0003e;&#x02009;12</td><td align="left">1110(46.0)</td><td align="left">629(44.8)</td><td align="left">98(53.1)</td><td align="left" colspan="2">383(46.7)</td></tr><tr><td align="left"><bold>Smoking status</bold>, <bold>n (%)</bold></td><td align="left">1646(55.2)</td><td align="left">926(52.3)</td><td align="left">130(56.4)</td><td align="left">590(60.0)</td><td align="left">0.014</td></tr><tr><td align="left"><bold>Alcohol using</bold>, <bold>n (%)</bold></td><td align="left">2216(77.9)</td><td align="left">1295(84.7)</td><td align="left">162(82.1)</td><td align="left">759(88.2)</td><td align="left">0.066</td></tr><tr><td align="left"><bold>BMI (kg/m2)</bold>, <bold>SD</bold></td><td align="left">28.3&#x02009;&#x000b1;&#x02009;0.1</td><td align="left">27.7&#x02009;&#x000b1;&#x02009;0.2</td><td align="left">28.8&#x02009;&#x000b1;&#x02009;0.5</td><td align="left">29.1&#x02009;&#x000b1;&#x02009;0.2</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left"><bold>LDL-C (mg/dl)</bold>, <bold>SD</bold></td><td align="left">110.7&#x02009;&#x000b1;&#x02009;1.3</td><td align="left">123.1&#x02009;&#x000b1;&#x02009;1.6</td><td align="left">94.1&#x02009;&#x000b1;&#x02009;3.5</td><td align="left">91.9&#x02009;&#x000b1;&#x02009;1.8</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left"><bold>HDL-C (mg/dl)</bold>, <bold>SD</bold></td><td align="left">55.8&#x02009;&#x000b1;&#x02009;0.4</td><td align="left">57.5&#x02009;&#x000b1;&#x02009;0.6</td><td align="left">52.7&#x02009;&#x000b1;&#x02009;1.4</td><td align="left">53.5&#x02009;&#x000b1;&#x02009;0.7</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left"><bold>TC (mg/dl)</bold>, <bold>SD</bold></td><td align="left">192.9&#x02009;&#x000b1;&#x02009;1.1</td><td align="left">207.9&#x02009;&#x000b1;&#x02009;1.2</td><td align="left">169.1&#x02009;&#x000b1;&#x02009;2.7</td><td align="left">171.9&#x02009;&#x000b1;&#x02009;1.7</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left"><bold>TG (mg/dl)</bold>, <bold>SD</bold></td><td align="left">150.9&#x02009;&#x000b1;&#x02009;2.4</td><td align="left">148.2&#x02009;&#x000b1;&#x02009;2.8</td><td align="left">155.2&#x02009;&#x000b1;&#x02009;7.5</td><td align="left">154.6&#x02009;&#x000b1;&#x02009;4.1</td><td align="left">0.294</td></tr><tr><td align="left"><bold>Family DM</bold>, <bold>n (%)</bold></td><td align="left">1088(36.2)</td><td align="left">610(34.3)</td><td align="left">87(38.4)</td><td align="left">391(39.0)</td><td align="left">0.240</td></tr><tr><td align="left"><bold>Family CVD</bold>, <bold>n (%)</bold></td><td align="left">356(13.3)</td><td align="left">183(11.6)</td><td align="left">37(17.9)</td><td align="left">136(15.3)</td><td align="left">0.024</td></tr><tr><td align="left"><bold>CVD</bold>, <bold>n (%)</bold></td><td align="left">937(29.4)</td><td align="left">423(22.9)</td><td align="left">92(39.0)</td><td align="left">422(38.7)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left"><bold>Hypertension</bold>, <bold>n (%)</bold></td><td align="left">2377(79.6)</td><td align="left">1360(76.7)</td><td align="left">186(86.2)</td><td align="left">831(83.4)</td><td align="left">0.005</td></tr><tr><td align="left"><bold>DM</bold>, <bold>n (%)</bold></td><td align="left">891(27.6)</td><td align="left">419(21.9)</td><td align="left">80(37.2)</td><td align="left">392(35.6)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left"><bold>Dyslipidemia</bold>, <bold>n (%)</bold></td><td align="left">747(25.0)</td><td align="left">496(30.8)</td><td align="left">51(25.0)</td><td align="left">200(20.5)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr></tbody></table><table-wrap-foot><p><italic>Abbreviations</italic> BMI, Body mass index; LDL-C Low-density lipoprotein-C; HDL-C high-density lipoprotein cholesterol; TC, Total cholesterol; TG, triglyceride; CVD: cardiovascular disease; DM, diabetes mellitus</p></table-wrap-foot></table-wrap>
</p><p id="Par23">The Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> illustrates survival probability over time for two statin users and non-user groups, showing significant differences in survival rates (<italic>P</italic>&#x02009;=&#x02009;0.010). The risk table provides detailed counts of individuals at various time points, reflecting changes in survival across the groups. In contrast to nonuser group, the cohort prescribed hydrophilic statins did not exhibit a diminished risk in terms of all-cause mortality (adjusted hazard ratio [HR], 1.01; 95% confidence interval [CI], 0.72&#x02013;1.41; <italic>P</italic>&#x02009;=&#x02009;0.960), as delineated in Model 3 (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Conversely, a significant reduction in all-cause mortality risk was observed in the cohort administered lipophilic statins (adjusted HR, 0.77; <italic>P</italic>&#x02009;=&#x02009;0.003). To elucidate the underlying causes of mortality in greater detail, we analyzed subsets of patients who succumbed to cancer-related fatalities, cardiovascular incidents, or other mortality etiologies. Notably, those administered lipophilic statins all demonstrated a significantly diminished cancer mortality risk, cardiovascular mortality risk, and other mortality in comparison to those abstaining from statin usage in model 3 (adjusted HR 0.70; 95% CI, 0.51&#x02013;0.95; adjusted HR, 0.70; 95% CI, 0.50&#x02013;0.99; adjusted HR, 0.70; 95% CI, 0.53&#x02013;0.92; respectively). Similar results were presented in sensitivity analyses excluding deaths within two years (eTable&#x000a0;2).</p><p id="Par24">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Kaplan&#x02013;Meier survival analysis curves for all-cause mortality</p></caption><graphic xlink:href="40520_2024_2851_Fig2_HTML" id="d33e909"/></fig>
</p><p id="Par25">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Comparative hazard ratios (HR) of statin users and nonusers on different causes of mortality across three models&#x02014;NHANES 1999&#x02013;2018</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Characteristics</th><th align="left" rowspan="2">Event/All population (weighted)</th><th align="left" colspan="2">Model 1</th><th align="left" colspan="2">Model 2</th><th align="left" colspan="2">Model 3</th></tr><tr><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic>-value</th><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic>-value</th><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left">
<bold>All-cause mortality</bold>
</td><td align="left">1471/4,420,636</td><td align="left" colspan="2"/><td align="left" colspan="2"/><td align="left" colspan="2"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No statin</td><td align="left"/><td align="left">Reference</td><td align="left">-</td><td align="left">Reference</td><td align="left">-</td><td align="left">Reference</td><td align="left">-</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Statin</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hydrophilic statins</td><td align="left"/><td align="left">1.06(0.78,1.44)</td><td align="left">0.700</td><td align="left">1.01(0.76,1.32)</td><td align="left">0.960</td><td align="left">1.01(0.72,1.41)</td><td align="left">0.960</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Lipophilic statins (The rest)</td><td align="left"/><td align="left">0.82(0.71,0.94)</td><td align="left">0.010</td><td align="left">0.85(0.75,0.97)</td><td align="left">0.020</td><td align="left">0.77(0.65,0.91)</td><td align="left">0.003</td></tr><tr><td align="left">
<bold>Cancer mortality</bold>
</td><td align="left">422/1,238,284</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No statin</td><td align="left"/><td align="left">Reference</td><td align="left">-</td><td align="left">Reference</td><td align="left">-</td><td align="left">Reference</td><td align="left">-</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Statin</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hydrophilic statins</td><td align="left"/><td align="left">0.80(0.46,1.39)</td><td align="left">0.430</td><td align="left">0.72(0.43,1.22)</td><td align="left">0.220</td><td align="left">0.70(0.37,1.34)</td><td align="left">0.280</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Lipophilic statins (The rest)</td><td align="left"/><td align="left">0.71(0.55,0.91)</td><td align="left">0.010</td><td align="left">0.67(0.52,0.86)</td><td align="left">0.001</td><td align="left">0.70(0.51,0.95)</td><td align="left">0.020</td></tr><tr><td align="left">
<bold>Cardiovascular mortality</bold>
</td><td align="left">415/1,247,440</td><td align="left" colspan="2"/><td align="left" colspan="2"/><td align="left" colspan="2"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No statin</td><td align="left"/><td align="left">Reference</td><td align="left">-</td><td align="left">Reference</td><td align="left">-</td><td align="left">Reference</td><td align="left">-</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Statin</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hydrophilic statins</td><td align="left"/><td align="left">1.23(0.72,2.13)</td><td align="left">0.450</td><td align="left">1.11(0.65,1.90)</td><td align="left">0.690</td><td align="left">1.08(0.53,2.20)</td><td align="left">0.840</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Lipophilic statins (The rest)</td><td align="left"/><td align="left">0.83(0.63,1.09)</td><td align="left">0.180</td><td align="left">0.87(0.69,1.11)</td><td align="left">0.280</td><td align="left">0.70(0.50,0.99)</td><td align="left">0.040</td></tr><tr><td align="left">
<bold>Other mortality</bold>
</td><td align="left">634/1,934,912</td><td align="left" colspan="2"/><td align="left" colspan="2"/><td align="left" colspan="2"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No statin</td><td align="left"/><td align="left">Reference</td><td align="left">-</td><td align="left">Reference</td><td align="left">-</td><td align="left">Reference</td><td align="left">-</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Statin</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hydrophilic statins</td><td align="left"/><td align="left">0.87(0.59,1.28)</td><td align="left">0.490</td><td align="left">0.85(0.59,1.22)</td><td align="left">0.380</td><td align="left">0.87(0.57,1.32)</td><td align="left">0.500</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Lipophilic statins (The rest)</td><td align="left"/><td align="left">0.74(0.59,0.93)</td><td align="left">0.010</td><td align="left">0.82(0.65,1.03)</td><td align="left">0.090</td><td align="left">0.70(0.53,0.92)</td><td align="left">0.010</td></tr></tbody></table><table-wrap-foot><p>Model 1: Adjusted for age. Model 2: Adjusted for age, sex, and race. Model 3: Adjusted for age, sex, race, education level, body mass index, alcohol use, smoking status, family diabetes mellitus, family cardiovascular disease, diabetes mellitus, cardiovascular disease, dyslipidemia, hypertension and years since the first cancer diagnosis</p><p>CI, Confidence interval; HR, Hazard ratio</p></table-wrap-foot></table-wrap>
</p><p id="Par26">To further clarify the relationship between statin use and the long-term prognosis of cancer survivors, we compiled the statin use from the onset of cancer to death in ageing cancer population (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). The population taking lipophilic statins after cancer diagnosis showed a decreased risk of mortality in all adjusted models including all-cause mortality (HR, 0.71, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, in Model 3), cancer-specific mortality (HR, 0.63, <italic>P</italic>&#x02009;=&#x02009;0.003, in Model 3), cardiovascular mortality (HR, 0.52, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, in Model 3), and mortality due to other causes (HR, 0.69, <italic>P</italic>&#x02009;=&#x02009;0.005, in Model 3).</p><p id="Par27">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Comparative hazard ratios (HR) for statin users Versus nonusers regarding mortality from cancer onset to death, across three analytical models&#x02014;NHANES 1999&#x02013;2018</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Characteristics</th><th align="left" colspan="2">Model 1</th><th align="left" colspan="2">Model 2</th><th align="left" colspan="2">Model 3</th></tr><tr><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic>-value</th><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic>-value</th><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left">
<bold>All-cause mortality</bold>
</td><td align="left" colspan="2"/><td align="left" colspan="2"/><td align="left" colspan="2"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No statin</td><td align="left">Reference</td><td align="left">-</td><td align="left">Reference</td><td align="left">-</td><td align="left">Reference</td><td align="left">-</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Statin</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hydrophilic statins</td><td align="left">0.81(0.57,1.16)</td><td align="left">0.250</td><td align="left">0.74(0.52,1.05)</td><td align="left">0.090</td><td align="left">0.64(0.44,0.92)</td><td align="left">0.020</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Lipophilic statins (The rest)</td><td align="left">0.76(0.65,0.90)</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">0.75(0.64,0.88)</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">0.71(0.60,0.84)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">
<bold>Cancer mortality</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No statin</td><td align="left">Reference</td><td align="left">-</td><td align="left">Reference</td><td align="left">-</td><td align="left">Reference</td><td align="left">-</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Statin</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hydrophilic statins</td><td align="left">0.73(0.38,1.39)</td><td align="left">0.330</td><td align="left">0.61(0.33,1.13)</td><td align="left">0.120</td><td align="left">0.49(0.25,0.96)</td><td align="left">0.040</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Lipophilic statins (The rest)</td><td align="left">0.68(0.52,0.89)</td><td align="left">0.004</td><td align="left">0.62(0.48,0.81)</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">0.63(0.46,0.85)</td><td align="left">0.003</td></tr><tr><td align="left">
<bold>Cardiovascular mortality</bold>
</td><td align="left" colspan="2"/><td align="left" colspan="2"/><td align="left" colspan="2"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No statin</td><td align="left">Reference</td><td align="left">-</td><td align="left">Reference</td><td align="left">-</td><td align="left">Reference</td><td align="left">-</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Statin</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hydrophilic statins</td><td align="left">0.87(0.47,1.62)</td><td align="left">0.660</td><td align="left">0.66(0.34,1.29)</td><td align="left">0.220</td><td align="left">0.48(0.23,1.00)</td><td align="left">0.050</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Lipophilic statins (The rest)</td><td align="left">0.70(0.51,0.97)</td><td align="left">0.030</td><td align="left">0.66(0.49,0.89)</td><td align="left">0.010</td><td align="left">0.52(0.36,0.74)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">
<bold>Other mortality</bold>
</td><td align="left" colspan="2"/><td align="left" colspan="2"/><td align="left" colspan="2"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No statin</td><td align="left">Reference</td><td align="left">-</td><td align="left">Reference</td><td align="left">-</td><td align="left">Reference</td><td align="left">-</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Statin</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hydrophilic statins</td><td align="left">0.61(0.40,0.93)</td><td align="left">0.020</td><td align="left">0.55(0.35,0.84)</td><td align="left">0.010</td><td align="left">0.51(0.32,0.83)</td><td align="left">0.010</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Lipophilic statins (The rest)</td><td align="left">0.69(0.53,0.89)</td><td align="left">0.010</td><td align="left">0.72(0.56,0.92)</td><td align="left">0.010</td><td align="left">0.69(0.53,0.89)</td><td align="left">0.005</td></tr></tbody></table><table-wrap-foot><p>Model 1: Adjusted for age. Model 2: Adjusted for age, sex, and race. Model 3: Adjusted for age, sex, race, education level, body mass index, alcohol use, smoking status, family diabetes mellitus, family cardiovascular disease, diabetes mellitus, cardiovascular disease, dyslipidemia, hypertension and years since the first cancer diagnosis</p><p>CI, Confidence interval; HR, Hazard ratio</p></table-wrap-foot></table-wrap>
</p><p id="Par28">Similar patterns were observed for the aging cancer survivors taking hydrophilic statins. The users of hydrophilic statins showed a reduction in all-cause mortality risk (HR, 0.64, <italic>P</italic>&#x02009;=&#x02009;0.020) and cancer-specific mortality (HR, 0.49, <italic>P</italic>&#x02009;=&#x02009;0.040), cardiovascular mortality (HR, 0.48, <italic>P</italic>&#x02009;=&#x02009;0.050), and mortality due to other causes (HR, 0.51, <italic>P</italic>&#x02009;=&#x02009;0.010) in the most comprehensive model.</p></sec><sec id="Sec10" sec-type="discussion"><title>Discussion</title><p id="Par29">The aging cancer survivors taking statins may exhibited decreased all-cause mortality risk, cancer-cause mortality risk, and also the risk of cardiovascular mortality, and other mortality. Notably, lipophilic statins are significantly associated with lower all-cause and cancer-cause mortality risks among aging cancer survivors.</p><p id="Par30">Previous studies showed statins use significantly diminishes the mortality rate in breast cancer patients [<xref ref-type="bibr" rid="CR7">7</xref>]. Prior investigations have shown that extended use of statin drugs might lower the risk of developing pancreatic cancer [<xref ref-type="bibr" rid="CR26">26</xref>], whereas the administration of statins, notably simvastatin, has been linked to a reduced risk of breast cancer relapse [<xref ref-type="bibr" rid="CR27">27</xref>]. Moreover, a marked reduction in both all-cause and cancer-specific mortality rates has been associated with statin use in aging individuals diagnosed with rectal cancer [<xref ref-type="bibr" rid="CR28">28</xref>]. In align with their reports, our study extends the benefit of statins use to the general aging cancer survivor demographic. Another interesting finding from our study is that elderly cancer survivors who use statins exhibit lower LDL-C levels compared to those who do not use statins. Guidelines recommend that patients with a moderate (7.5% to &#x0003c;&#x02009;20%) and high (&#x0003e;&#x02009;20%) 10-year ASCVD risk score should consider moderate and high-intensity statin therapy, respectively [<xref ref-type="bibr" rid="CR29">29</xref>]. Compared to the general population, survivors of various adult cancers face an increased medium to long-term risk of cardiovascular diseases (including heart failure, coronary artery disease, arrhythmias, stroke, and venous thromboembolism) [<xref ref-type="bibr" rid="CR30">30</xref>]. This suggest that the benefits of statin medication may stem from lipid reduction.</p><p id="Par31">Our research highlights the more significant effect of lipophilic statins in preventing mortality within this population, compared with hydrophilic statins. Consistently, earlier studies have emphasized the superiority of lipophilic statins over hydrophilic ones in mitigating complications associated with hepatocellular carcinoma [<xref ref-type="bibr" rid="CR31">31</xref>]. Furthermore, a meticulous subgroup analysis revealed that this benefit is magnified in male survivors who are above the age of 65, particularly in those grappling with obesity, hypertension, dyslipidemia, and in individuals who are not diabetic. However, we found that both hydrophilic and lipophilic statins are effective in lowering the risk of cancer in aging cancer survivors from the onset of cancer to death, with hydrophilic statins demonstrating superior efficacy.</p><p id="Par32">If statin medications prove to be effective in battling tumor growth, potentially serving as a more strategic and well-tolerated alternative to traditional chemotherapy agents [<xref ref-type="bibr" rid="CR32">32</xref>], this prospect unveils fresh trajectories for upcoming research endeavors. Subsequent studies can delve deeper into the viable applications of statin drugs, either as standalone agents or in synergy with other medications, in both the prevention and treatment of cancer [<xref ref-type="bibr" rid="CR27">27</xref>]. These discoveries carry substantial clinical relevance [<xref ref-type="bibr" rid="CR33">33</xref>], signaling a potentially promising therapeutic pathway in clinical settings. More precisely, the deployment of lipophilic statin medications might establish a targeted modality to mitigate the mortality risk stemming from cardiac events and malignancies [<xref ref-type="bibr" rid="CR34">34</xref>]. This positive association could signify a groundbreaking shift in the medical management strategies for cancer survivors, facilitating improved survival rates and elevating their life quality [<xref ref-type="bibr" rid="CR35">35</xref>]. Looking forward, comprehensive investigations are imperative to fully delineate the extent and possible applications of these encouraging findings within the clinical sphere, laying the groundwork for bespoke treatment plans for individuals who have overcome cancer [<xref ref-type="bibr" rid="CR36">36</xref>]. The intrigue generated by these findings concerning the prospective role of statin drugs in cancer therapy sets a robust platform for forthcoming research initiatives and clinical integrations [<xref ref-type="bibr" rid="CR37">37</xref>].</p><sec id="Sec11"><title>Limitations</title><p id="Par33">Our study presents several notable limitations. Firstly, it is important to recognize that as an observational study, there are inherent limitations in controlling for all potential confounding factors. While we have made efforts to adjust for known confounders in the Models 1&#x02013;4, there may still be unmeasured or unaccounted variable. Consequently, we cannot offer definitive proof of causation. But we conducted sensitivity analyses excluding deaths within two years, which reduces the possibility of reverse causation. Secondly, the utilization of self-reported data for defining key variables like age, gender, and race introduces a potential bias, as this data might not be entirely accurate or reflective of the actual parameters. Thirdly, our categorization of participants, particularly in relation to statin use, might overshadow more subtle effects of different statins on individuals, thereby not encapsulating the complex realities of patient experiences fully.</p></sec></sec><sec id="Sec12" sec-type="conclusion"><title>Conclusion</title><p id="Par34">In this study, we identified a significant potential role for statin use, particularly lipophilic statins, in reducing all-cause, cardiovascular, and cancer-specific mortality among aging cancer survivors. Our findings propose the statins may improve the outcomes of aging cancer survivors and provide an insight for a new therapeutic strategy for cancer management.</p></sec><sec id="Sec13" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="40520_2024_2851_MOESM1_ESM.docx"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="40520_2024_2851_MOESM2_ESM.docx"><caption><p>Supplementary Material 2</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Shan Ding, Fengling Yang and Pan Lai contributed equally to this work.</p></fn><fn><p><bold>Change history</bold></p><p>12/5/2024</p><p id="Par501">The original online version of this article was revised to update the incorrect affiliation details of author Jiang Weiwen1, 4, Minze Chen5, Yijun Ge 6, and Ye Yanrong 1, 4</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors thank the participants and staff of the NHANES database for their valuable contributions.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>YRY designed the research and is the guarantor of this work. SD had full access to all data used in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. SD, FLY and PL performed the analyses and wrote the first draft of the manuscript. WWJ, MZC, YJG, LTZ, SZC and JQZ revised the manuscript. All authors read and approved the final manuscript and its submission.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethical approval</title><p id="Par38">The project was authorized by the National Center for Health Statistics Research Ethics Review Board (Protocol #98&#x02009;&#x02212;&#x02009;12, Protocol #2005-06, Protocol #2011-17, Protocol #2018-01). Participants were included from US National Health and Nutrition Examination Survey (NHANES) 1999&#x02013;2018.</p></notes><notes id="FPar2"><title>Consent to participate</title><p id="Par39">Written informed consent was obtained from all participants or their parents/guardians.</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par36">Not applicable.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests</title><p id="Par37">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Rock</surname><given-names>CL</given-names></name><etal/></person-group><article-title>American Cancer Society nutrition and physical activity guideline for cancer survivors</article-title><source>CA Cancer J Clin</source><year>2022</year><volume>72</volume><issue>3</issue><fpage>230</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.3322/caac.21719</pub-id><pub-id pub-id-type="pmid">35294043</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Rock CL et al (2022) American Cancer Society nutrition and physical activity guideline for cancer survivors. CA Cancer J Clin 72(3):230&#x02013;262<pub-id pub-id-type="pmid">35294043</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>RE</given-names></name><etal/></person-group><article-title>United States Population-based estimates of patient-reported outcomes Measurement Information System Symptom and Functional Status reference values for individuals with Cancer</article-title><source>J Clin Oncol</source><year>2017</year><volume>35</volume><issue>17</issue><fpage>1913</fpage><lpage>1920</lpage><pub-id pub-id-type="doi">10.1200/JCO.2016.71.4410</pub-id><pub-id pub-id-type="pmid">28426375</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Jensen RE et al (2017) United States Population-based estimates of patient-reported outcomes Measurement Information System Symptom and Functional Status reference values for individuals with Cancer. J Clin Oncol 35(17):1913&#x02013;1920<pub-id pub-id-type="pmid">28426375</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>R</given-names></name><etal/></person-group><article-title>Interpretation of the evidence for the efficacy and safety of statin therapy</article-title><source>Lancet</source><year>2016</year><volume>388</volume><issue>10059</issue><fpage>2532</fpage><lpage>2561</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)31357-5</pub-id><pub-id pub-id-type="pmid">27616593</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Collins R et al (2016) Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388(10059):2532&#x02013;2561<pub-id pub-id-type="pmid">27616593</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>BK</given-names></name><etal/></person-group><article-title>Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial</article-title><source>Lancet</source><year>2022</year><volume>400</volume><issue>10349</issue><fpage>380</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)00916-3</pub-id><pub-id pub-id-type="pmid">35863366</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Kim BK et al (2022) Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet 400(10349):380&#x02013;390<pub-id pub-id-type="pmid">35863366</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>CW</given-names></name></person-group><article-title>Statins in therapy: understanding their hydrophilicity, lipophilicity, binding to 3-hydroxy-3-methylglutaryl-CoA reductase, ability to cross the blood brain barrier and metabolic stability based on electrostatic molecular orbital studies</article-title><source>Eur J Med Chem</source><year>2014</year><volume>85</volume><fpage>661</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2014.08.037</pub-id><pub-id pub-id-type="pmid">25128668</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Fong CW (2014) Statins in therapy: understanding their hydrophilicity, lipophilicity, binding to 3-hydroxy-3-methylglutaryl-CoA reductase, ability to cross the blood brain barrier and metabolic stability based on electrostatic molecular orbital studies. Eur J Med Chem 85:661&#x02013;674<pub-id pub-id-type="pmid">25128668</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>WT</given-names></name><etal/></person-group><article-title>Association of Statin Use with Cancer- and Noncancer-Associated Survival among patients with breast Cancer in Asia</article-title><source>JAMA Netw Open</source><year>2023</year><volume>6</volume><issue>4</issue><fpage>e239515</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.9515</pub-id><pub-id pub-id-type="pmid">37083661</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Chang WT et al (2023) Association of Statin Use with Cancer- and Noncancer-Associated Survival among patients with breast Cancer in Asia. JAMA Netw Open 6(4):e239515<pub-id pub-id-type="pmid">37083661</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>OW</given-names></name><etal/></person-group><article-title>Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study</article-title><source>Breast Cancer Res Treat</source><year>2023</year><volume>199</volume><issue>1</issue><fpage>195</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1007/s10549-022-06815-w</pub-id><pub-id pub-id-type="pmid">36930345</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Scott OW et al (2023) Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study. Breast Cancer Res Treat 199(1):195&#x02013;206<pub-id pub-id-type="pmid">36930345</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Statin use is Associated with Better prognosis of patients with prostate Cancer after definite therapies: a systematic review and Meta-analysis of Cohort studies</article-title><source>J Oncol</source><year>2022</year><volume>2022</volume><fpage>p9275466</fpage><pub-id pub-id-type="doi">10.1155/2022/9275466</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">An Y et al (2022) Statin use is Associated with Better prognosis of patients with prostate Cancer after definite therapies: a systematic review and Meta-analysis of Cohort studies. J Oncol 2022:p9275466</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Bardou</surname><given-names>M</given-names></name><name><surname>Barkun</surname><given-names>A</given-names></name><name><surname>Martel</surname><given-names>M</given-names></name></person-group><article-title>Effect of statin therapy on colorectal cancer</article-title><source>Gut</source><year>2010</year><volume>59</volume><issue>11</issue><fpage>1572</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.1136/gut.2009.190900</pub-id><pub-id pub-id-type="pmid">20660702</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Bardou M, Barkun A, Martel M (2010) Effect of statin therapy on colorectal cancer. Gut 59(11):1572&#x02013;1585<pub-id pub-id-type="pmid">20660702</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>Cho</surname><given-names>E</given-names></name></person-group><article-title>Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts</article-title><source>Cancer</source><year>2012</year><volume>118</volume><issue>3</issue><fpage>797</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1002/cncr.26338</pub-id><pub-id pub-id-type="pmid">21751202</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Liu W, Choueiri TK, Cho E (2012) Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts. Cancer 118(3):797&#x02013;803<pub-id pub-id-type="pmid">21751202</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>KK</given-names></name><name><surname>Oza</surname><given-names>AM</given-names></name><name><surname>Siu</surname><given-names>LL</given-names></name></person-group><article-title>The statins as anticancer agents</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><issue>1</issue><fpage>10</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">12538446</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9(1):10&#x02013;19<pub-id pub-id-type="pmid">12538446</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Koushki</surname><given-names>K</given-names></name><etal/></person-group><article-title>Anti-inflammatory action of statins in Cardiovascular Disease: the role of Inflammasome and Toll-Like receptor pathways</article-title><source>Clin Rev Allergy Immunol</source><year>2021</year><volume>60</volume><issue>2</issue><fpage>175</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1007/s12016-020-08791-9</pub-id><pub-id pub-id-type="pmid">32378144</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Koushki K et al (2021) Anti-inflammatory action of statins in Cardiovascular Disease: the role of Inflammasome and Toll-Like receptor pathways. Clin Rev Allergy Immunol 60(2):175&#x02013;199<pub-id pub-id-type="pmid">32378144</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Tobert</surname><given-names>JA</given-names></name></person-group><article-title>Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors</article-title><source>Nat Rev Drug Discov</source><year>2003</year><volume>2</volume><issue>7</issue><fpage>517</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1038/nrd1112</pub-id><pub-id pub-id-type="pmid">12815379</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Tobert JA (2003) Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2(7):517&#x02013;526<pub-id pub-id-type="pmid">12815379</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Jakobisiak</surname><given-names>M</given-names></name><name><surname>Golab</surname><given-names>J</given-names></name></person-group><article-title>Potential antitumor effects of statins (review)</article-title><source>Int J Oncol</source><year>2003</year><volume>23</volume><issue>4</issue><fpage>1055</fpage><lpage>1069</lpage><pub-id pub-id-type="pmid">12963986</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Jakobisiak M, Golab J (2003) Potential antitumor effects of statins (review). Int J Oncol 23(4):1055&#x02013;1069<pub-id pub-id-type="pmid">12963986</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Hamelin</surname><given-names>BA</given-names></name><name><surname>Turgeon</surname><given-names>J</given-names></name></person-group><article-title>Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors</article-title><source>Trends Pharmacol Sci</source><year>1998</year><volume>19</volume><issue>1</issue><fpage>26</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/S0165-6147(97)01147-4</pub-id><pub-id pub-id-type="pmid">9509899</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Hamelin BA, Turgeon J (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19(1):26&#x02013;37<pub-id pub-id-type="pmid">9509899</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Dulak</surname><given-names>J</given-names></name><name><surname>J&#x000f3;zkowicz</surname><given-names>A</given-names></name></person-group><article-title>Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy</article-title><source>Curr Cancer Drug Targets</source><year>2005</year><volume>5</volume><issue>8</issue><fpage>579</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.2174/156800905774932824</pub-id><pub-id pub-id-type="pmid">16375664</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Dulak J, J&#x000f3;zkowicz A (2005) Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets 5(8):579&#x02013;594<pub-id pub-id-type="pmid">16375664</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Menter</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><issue>12</issue><fpage>e28813</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0028813</pub-id><pub-id pub-id-type="pmid">22216116</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Menter DG et al (2011) Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. PLoS ONE 6(12):e28813<pub-id pub-id-type="pmid">22216116</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>TS</given-names></name><etal/></person-group><article-title>Serum cholesterol differences between statin users who take dietary supplements and those who do not: NHANES 2013&#x02013;2018</article-title><source>Curr Dev Nutr</source><year>2023</year><volume>7</volume><issue>1</issue><fpage>100007</fpage><pub-id pub-id-type="doi">10.1016/j.cdnut.2022.100007</pub-id><pub-id pub-id-type="pmid">37181126</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">MacDonald TS et al (2023) Serum cholesterol differences between statin users who take dietary supplements and those who do not: NHANES 2013&#x02013;2018. Curr Dev Nutr 7(1):100007<pub-id pub-id-type="pmid">37181126</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Hicks</surname><given-names>CW</given-names></name><etal/></person-group><article-title>Peripheral neuropathy and all-cause and Cardiovascular Mortality in U.S. adults: a prospective cohort study</article-title><source>Ann Intern Med</source><year>2021</year><volume>174</volume><issue>2</issue><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.7326/M20-1340</pub-id><pub-id pub-id-type="pmid">33284680</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Hicks CW et al (2021) Peripheral neuropathy and all-cause and Cardiovascular Mortality in U.S. adults: a prospective cohort study. Ann Intern Med 174(2):167&#x02013;174<pub-id pub-id-type="pmid">33284680</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Chamberlain</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Treatment of type 1 diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes</article-title><source>Ann Intern Med</source><year>2017</year><volume>167</volume><issue>7</issue><fpage>493</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.7326/M17-1259</pub-id><pub-id pub-id-type="pmid">28892816</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Chamberlain JJ et al (2017) Treatment of type 1 diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med 167(7):493&#x02013;498<pub-id pub-id-type="pmid">28892816</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Whelton</surname><given-names>PK</given-names></name><etal/></person-group><article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines</article-title><source>J Am Coll Cardiol</source><year>2018</year><volume>71</volume><issue>19</issue><fpage>e127</fpage><lpage>e248</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2017.11.006</pub-id><pub-id pub-id-type="pmid">29146535</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Whelton PK et al (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines. J Am Coll Cardiol 71(19):e127&#x02013;e248<pub-id pub-id-type="pmid">29146535</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>K</given-names></name><etal/></person-group><article-title>Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: from National Health and Nutrition Examination Survey</article-title><source>Prog Cardiovasc Dis</source><year>2022</year><volume>75</volume><fpage>78</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.pcad.2022.08.007</pub-id><pub-id pub-id-type="pmid">36038004</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Gupta K et al (2022) Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: from National Health and Nutrition Examination Survey. Prog Cardiovasc Dis 75:78&#x02013;82<pub-id pub-id-type="pmid">36038004</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Q</given-names></name><etal/></person-group><article-title>L-shaped association of serum 25-hydroxyvitamin D concentrations with cardiovascular and all-cause mortality in individuals with osteoarthritis: results from the NHANES database prospective cohort study</article-title><source>BMC Med</source><year>2022</year><volume>20</volume><issue>1</issue><fpage>308</fpage><pub-id pub-id-type="doi">10.1186/s12916-022-02510-1</pub-id><pub-id pub-id-type="pmid">36127705</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Xiao Q et al (2022) L-shaped association of serum 25-hydroxyvitamin D concentrations with cardiovascular and all-cause mortality in individuals with osteoarthritis: results from the NHANES database prospective cohort study. BMC Med 20(1):308<pub-id pub-id-type="pmid">36127705</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Okedele</surname><given-names>OO</given-names></name><etal/></person-group><article-title>Cytomegalovirus and cancer-related mortality in the national health and nutritional examination survey</article-title><source>Cancer Causes Control</source><year>2020</year><volume>31</volume><issue>6</issue><fpage>541</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1007/s10552-020-01296-y</pub-id><pub-id pub-id-type="pmid">32222844</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Okedele OO et al (2020) Cytomegalovirus and cancer-related mortality in the national health and nutritional examination survey. Cancer Causes Control 31(6):541&#x02013;547<pub-id pub-id-type="pmid">32222844</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Trends in Diet Quality among Youth in the United States, 1999&#x02013;2016</article-title><source>JAMA</source><year>2020</year><volume>323</volume><issue>12</issue><fpage>1161</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.0878</pub-id><pub-id pub-id-type="pmid">32207798</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Liu J et al (2020) Trends in Diet Quality among Youth in the United States, 1999&#x02013;2016. JAMA 323(12):1161&#x02013;1174<pub-id pub-id-type="pmid">32207798</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Zhang Y et al (2019) Statin use and risk of pancreatic Cancer: an updated Meta-analysis of 26 studies. 48(2):142&#x02013;150</mixed-citation></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Ahern</surname><given-names>TP</given-names></name><etal/></person-group><article-title>Statins and breast cancer prognosis: evidence and opportunities</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><issue>10</issue><fpage>e461</fpage><lpage>e468</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)70119-6</pub-id><pub-id pub-id-type="pmid">25186049</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Ahern TP et al (2014) Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncol 15(10):e461&#x02013;e468<pub-id pub-id-type="pmid">25186049</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Pourlotfi A et al (2021) Statin use and long-term mortality after rectal Cancer surgery. Cancers (Basel), 13(17)</mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Lloyd-Jones DM et al (2019) Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology. 139(25):e1162&#x02013;e1177</mixed-citation></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Strongman</surname><given-names>H</given-names></name><etal/></person-group><article-title>Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases</article-title><source>Lancet</source><year>2019</year><volume>394</volume><issue>10203</issue><fpage>1041</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)31674-5</pub-id><pub-id pub-id-type="pmid">31443926</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Strongman H et al (2019) Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet 394(10203):1041&#x02013;1054<pub-id pub-id-type="pmid">31443926</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Facciorusso A et al (2020) Statin Use decreases the incidence of Hepatocellular Carcinoma: an updated Meta-analysis. Cancers (Basel), 12(4)</mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuoppala</surname><given-names>J</given-names></name><name><surname>Lamminp&#x000e4;&#x000e4;</surname><given-names>A</given-names></name><name><surname>Pukkala</surname><given-names>E</given-names></name></person-group><article-title>Statins and cancer: a systematic review and meta-analysis</article-title><source>Eur J Cancer</source><year>2008</year><volume>44</volume><issue>15</issue><fpage>2122</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2008.06.025</pub-id><pub-id pub-id-type="pmid">18707867</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Kuoppala J, Lamminp&#x000e4;&#x000e4; A, Pukkala E (2008) Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 44(15):2122&#x02013;2132<pub-id pub-id-type="pmid">18707867</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>SF</given-names></name><name><surname>Nordestgaard</surname><given-names>BG</given-names></name><name><surname>Bojesen</surname><given-names>SE</given-names></name></person-group><article-title>Statin use and reduced cancer-related mortality</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><issue>19</issue><fpage>1792</fpage><lpage>1802</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1201735</pub-id><pub-id pub-id-type="pmid">23134381</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367(19):1792&#x02013;1802<pub-id pub-id-type="pmid">23134381</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Bonovas</surname><given-names>S</given-names></name><etal/></person-group><article-title>Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><issue>34</issue><fpage>8606</fpage><lpage>8612</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.02.7045</pub-id><pub-id pub-id-type="pmid">16260694</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Bonovas S et al (2005) Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23(34):8606&#x02013;8612<pub-id pub-id-type="pmid">16260694</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>S</given-names></name><etal/></person-group><article-title>Statin use and mortality in cancer patients: systematic review and meta-analysis of observational studies</article-title><source>Cancer Treat Rev</source><year>2015</year><volume>41</volume><issue>6</issue><fpage>554</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2015.04.005</pub-id><pub-id pub-id-type="pmid">25890842</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Zhong S et al (2015) Statin use and mortality in cancer patients: systematic review and meta-analysis of observational studies. Cancer Treat Rev 41(6):554&#x02013;567<pub-id pub-id-type="pmid">25890842</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Thurnher</surname><given-names>M</given-names></name><name><surname>Nussbaumer</surname><given-names>O</given-names></name><name><surname>Gruenbacher</surname><given-names>G</given-names></name></person-group><article-title>Novel aspects of mevalonate pathway inhibitors as antitumor agents</article-title><source>Clin Cancer Res</source><year>2012</year><volume>18</volume><issue>13</issue><fpage>3524</fpage><lpage>3531</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-0489</pub-id><pub-id pub-id-type="pmid">22529099</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Thurnher M, Nussbaumer O, Gruenbacher G (2012) Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res 18(13):3524&#x02013;3531<pub-id pub-id-type="pmid">22529099</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Poynter</surname><given-names>JN</given-names></name><etal/></person-group><article-title>Statins and the risk of colorectal cancer</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><issue>21</issue><fpage>2184</fpage><lpage>2192</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa043792</pub-id><pub-id pub-id-type="pmid">15917383</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Poynter JN et al (2005) Statins and the risk of colorectal cancer. N Engl J Med 352(21):2184&#x02013;2192<pub-id pub-id-type="pmid">15917383</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>